Search results for "Highlights"
HbA1c levels above 9% may be associated with higher dementia risk
A cohort study found higher dementia risk among type 2 diabetes patients ages 50 years and older whose HbA1c levels were usually in the 9% to 10% or 10% and above range compared to those with tighter glycemic control.
https://diabetes.acponline.org/archives/2023/05/12/2.htm
12 May 2023
Subscribe
ACP Diabetes Monthly delivers a monthly summary of news about diabetes, including the latest research, clinical guidelines, and FDA drug actions.
https://diabetes.acponline.org/subscribe/index.html
GLP-1 receptor agonists associated with better primary CV prevention vs. DPP-4 inhibitors
A retrospective study compared cardiovascular (CV) outcomes among patients adding glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 inhibitors, or dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin, sulfonylurea, or insulin treatment alone or in combination.
https://diabetes.acponline.org/archives/2023/05/12/3.htm
12 May 2023
Guaranteeing adequate carbs before postpartum oral glucose tolerance testing may not be necessary
An analysis of data from two prospective studies found no relationship between carbohydrate intake in the day or days before testing and glucose level 120 minutes after oral glucose tolerance testing.
https://diabetes.acponline.org/archives/2023/05/12/1.htm
12 May 2023
Report and study highlight risk of heart failure in patients with diabetes
The American Diabetes Association made recommendations on diagnosing and treating heart failure in patients with diabetes, and a study found increased risk of progression to clinical heart failure in those with an HbA1c level of 7% or above.
https://diabetes.acponline.org/archives/2022/06/10/1.htm
10 Jun 2022
ACP Journal Club: SGLT-2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes
The results of this meta-analysis of sodium-glucose cotransporter-2 (SGLT-2) inhibitors highlight the opportunity for internists, nephrologists, endocrinologists, and cardiologists to collaborate to expand use of the drug class, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/03/10/7.htm
10 Mar 2023
SGLT-2 inhibitors reduce cardiac events, mortality compared to DPP-4 inhibitors
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were associated with lower risk of cardiovascular events compared to dipeptidyl peptidase-4 (DPP-4) inhibitors but higher risk of genital infections and diabetic ketoacidosis, a retrospective study found.
https://diabetes.acponline.org/archives/2023/02/10/1.htm
10 Feb 2023
NSAID use linked to risk of heart failure hospitalization in type 2 diabetes
Danish patients with type 2 diabetes who took prescription NSAIDs had increased risk of first-time heart failure hospitalization, particularly if they were new users of the drugs or age 65 years or older, a recent study found.
https://diabetes.acponline.org/archives/2023/04/14/2.htm
14 Apr 2023
Younger patients often ration insulin due to cost, study finds
Data from the 2021 National Health Interview Survey indicate that one in five patients younger than age 65 years, who would not be eligible for the $35 monthly Medicare price cap, have skipped or reduced insulin doses or put off buying the drug to save money.
https://diabetes.acponline.org/archives/2023/04/14/3.htm
14 Apr 2023
High-sensitivity C-reactive protein level predicted mortality risk in recent-onset type 2 diabetes
While high-sensitivity C-reactive protein was a good predictor of mortality, C-peptide levels were more closely associated with cardiovascular events, and having high levels of both was associated with increased risk of either outcome, a prospective study in Denmark found.
https://diabetes.acponline.org/archives/2023/04/14/1.htm
14 Apr 2023